Mangosteen, Inflammation, And The 2015 Trial Everyone Mentions
The 2015 mangosteen human trial found that a mangosteen-based drink increased antioxidant capacity in healthy adults and also lowered a key inflammation marker, C-reactive protein, after 30 days; the standout result was a reported 15% rise in blood antioxidant capacity versus placebo and a 46% drop in CRP within the mangosteen group.
What the study tested
The trial was published in 2015 in Food Science & Nutrition and used a randomized, double-blind, placebo-controlled design, which is the kind of setup researchers use to reduce bias. It enrolled 60 healthy adults, evenly split by sex, and compared a mangosteen-based beverage with a placebo over a 30-day period.
The beverage was evaluated for its effects on oxidative stress, inflammation, immune markers, and basic safety labs such as liver and kidney function. In other words, this was not just a "does it work?" study, but also a "is it safe enough to drink daily?" study.
Key results
The most notable outcome was the antioxidant signal: the mangosteen group showed about 15% higher antioxidant capacity in the bloodstream than the placebo group after the intervention. The study also reported a 46% reduction in C-reactive protein, a widely used marker of systemic inflammation, in the mangosteen group from pre- to post-intervention.
At the same time, the trial found no significant change in several immune markers, including IgA, IgG, IgM, C3, and C4, and no adverse effects on liver or kidney function tests were reported. That makes the trial interesting because the signal was strongest for antioxidant capacity, with the inflammation result acting as a secondary but still attention-grabbing finding.
Why the result mattered
The reason this trial got attention is that it translated a fruit-associated antioxidant story into a human clinical setting rather than a lab dish or animal model. In human nutrition research, that matters because many antioxidant claims fail to show up clearly once tested in people under controlled conditions.
The result also fit a broader scientific pattern around mangosteen compounds, especially xanthones such as alpha-mangostin, which have been studied for anti-inflammatory activity in human cells and other models. Earlier mechanistic work suggested those compounds may dampen inflammatory signaling pathways linked to cytokine production and insulin resistance.
Study details
| Item | Details |
|---|---|
| Publication year | 2015 |
| Journal | Food Science & Nutrition |
| Design | Randomized, double-blind, placebo-controlled clinical trial |
| Participants | 60 healthy adults, ages 18 to 60 |
| Duration | 30 days |
| Main antioxidant measure | ORAC-based plasma antioxidant capacity |
| Main inflammation marker | C-reactive protein (CRP) |
| Reported antioxidant effect | 15% higher than placebo |
| Reported CRP change | 46% decrease within the mangosteen group |
How to read the evidence
The trial's findings are promising, but they should be interpreted as an early signal rather than final proof that mangosteen treats inflammation. A 60-person, 30-day study can suggest a biologic effect, yet it cannot establish long-term benefits, clinical outcomes, or whether the beverage would help people with chronic inflammatory disease.
There is also an important formulation issue: a separate 2015 human study on a mangosteen functional beverage noted that the product contained other ingredients, including aloe vera, green tea, and multivitamins, which means results from commercial drinks may reflect more than mangosteen alone. That is one reason later reviews described clinical evidence on mangosteen as encouraging but still inconclusive overall.
Context in 2015
In 2015, interest in "functional beverages" was growing, and mangosteen was often marketed as a high-antioxidant tropical fruit with potential wellness benefits. This trial landed in the middle of that trend and gave marketers and researchers a concrete human data point to cite, especially because it paired antioxidant capacity with an inflammation marker.
Still, the safest scientific takeaway is narrower than the marketing headlines. The study supports the idea that a mangosteen-based drink can affect blood biomarkers in healthy adults over a short period, but it does not prove disease prevention, treatment, or superiority over a balanced diet.
Practical takeaway
- The 2015 trial's biggest finding was improved antioxidant capacity in blood after 30 days.
- The second headline result was a sizable reduction in CRP, an inflammation marker, within the mangosteen group.
- The evidence was short-term and small, so it is best viewed as promising rather than definitive.
- Because some mangosteen products include multiple ingredients, product-specific claims should be checked carefully.
What researchers still need
Future studies would need larger samples, longer follow-up, and clearer testing of mangosteen alone versus blended beverage formulas. They should also measure whether biomarker changes translate into real health outcomes, not just lab values.
For now, the 2015 study remains a useful citation point because it showed a measurable antioxidant effect in humans and a notable inflammation signal, but in a controlled, modest-sized trial.
The 2015 mangosteen trial's standout result was not a vague "health boost," but a measurable rise in antioxidant capacity paired with a substantial CRP decline in healthy adults.
Helpful tips and tricks for Mangosteen Inflammation And The 2015 Trial Everyone Mentions
Was the 2015 mangosteen trial on real people?
Yes. It was a randomized, double-blind, placebo-controlled clinical trial in 60 healthy adults ages 18 to 60.
What was the main antioxidant finding?
The mangosteen group showed about 15% greater blood antioxidant capacity than the placebo group after 30 days.
Did it reduce inflammation?
The study reported a 46% drop in C-reactive protein within the mangosteen group, which is a meaningful inflammation signal, though the trial was short and small.
Was it proven to be safe?
Within this study, no adverse effects were reported for liver, kidney, or immune markers over 30 days.
Does this prove mangosteen is a treatment?
No. The trial supports a short-term biomarker effect, but it does not prove mangosteen treats inflammation-related disease.